Literature DB >> 20487607

Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain.

L Anibarro1, S Casas, J Paz-Esquete, L Gonzalez, A Pena, M R Guerra, D Sande, L Calviño, M Santin.   

Abstract

SETTING: Treatment of latent tuberculosis infection (LTBI) is essential for tuberculosis (TB) control in low-prevalence countries. However, the long treatment duration and adverse events frequently result in suboptimal treatment completion.
OBJECTIVE: To determine completion rates of LTBI treatment and to identify risk factors for non-completion of treatment.
DESIGN: Retrospective, observational cohort study.
METHODS: All non-human immunodeficiency virus infected adults who started treatment for LTBI at two specialist TB units in Spain between January 2004 and March 2007 were included. Those who discontinued treatment due to toxicity were excluded.
RESULTS: Of 599 people who started on treatment, 484 (80.8%, 95%CI 77.5-83.8) completed it. Age <36 years (OR 0.33, 95%CI 0.30-0.76, P = 0.001), male sex (OR 0.58, 95%CI 0.37-0.92, P = 0.02), immigrant status <5 years of residence (OR 0.21, 95%CI 0.12-0.37, P < 0.001) and the presence of social risk factors (OR 0.21, 95%CI 0.11-0.39, P < 0.001) were associated with lower rates of treatment completion. Short treatment regimens were not associated with better treatment completion compared with isoniazid for 6-9 months (OR 0.89, 95%CI 0.45-1.80, P = 0.76).
CONCLUSIONS: Overall, completion rates of LTBI treatment in specialist TB units are good. Nevertheless, counselling should be strengthened and new strategies to enhance adherence should be sought for recent immigrants and for people in unfavourable social situations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20487607

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies.

Authors:  E M Sánchez-García; R Gamallo; A Blanco-Moure; M A Viejo; L Amador; L Anibarro
Journal:  Infection       Date:  2013-06-05       Impact factor: 3.553

Review 2.  Tuberculosis in patients with haematological malignancies.

Authors:  Luis Anibarro; Alberto Pena
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-04-07       Impact factor: 2.576

3.  Tuberculosis preventive treatment in a single medical center and evaluation of the results.

Authors:  Beyhan Cakar; Nalan Demir; Demet Karnak; Seref Ozkara
Journal:  Exp Ther Med       Date:  2014-09-22       Impact factor: 2.447

4.  [Factors associated with treatment adherence for tuberculosis infection].

Authors:  Carmen R Gallardo; María Teresa Gea Velázquez de Castro; Juana Requena Puche; Juan José Miralles Bueno; María Vicenta Rigo Medrano; Jesús M Aranaz Andrés
Journal:  Aten Primaria       Date:  2013-12-09       Impact factor: 1.137

5.  Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic.

Authors:  Claudia C Dobler; Guy B Marks
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

6.  A recent HIV diagnosis is associated with non-completion of Isoniazid Preventive Therapy in an HIV-infected cohort in Cape Town.

Authors:  Tolu Oni; Relebohile Tsekela; Bekekile Kwaza; Lulama Manjezi; Nonzwakazi Bangani; Katalin A Wilkinson; David Coetzee; Robert J Wilkinson
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

Review 7.  Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review.

Authors:  Anke L Stuurman; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anouk M Oordt-Speets; Andreas Sandgren; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-06-08       Impact factor: 3.090

8.  Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.

Authors:  Andreas Sandgren; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anke Stuurman; Anouk Oordt-Speets; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-05-17       Impact factor: 3.090

9.  QuantiFERON®-TB Gold In-Tube for contact screening in BCG-vaccinated adults: A longitudinal cohort study.

Authors:  Laura Muñoz; Lucia Gonzalez; Laura Soldevila; Jordi Dorca; Fernando Alcaide; Miguel Santin
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.